Email Alert RSS
Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. DOI: 10.12290/xhyxzz.2022-0584
Citation: Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. DOI: 10.12290/xhyxzz.2022-0584
shu

Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-C-028

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-010

CAMS Innovation Fund for Medical Sciences 2022-I2M-JB-001

More Information
  • Received Date: October 08, 2022
  • Accepted Date: October 24, 2022
  • Available Online: November 06, 2022
  • Issue Publish Date: November 29, 2022
    Graphical Abstract
    • Abstract
  • Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that 68Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion of a group of multi-disciplinary experts, a consensus has been established, which covers imaging technology, interpretation of results of CXCR4 imaging, and the guidance to the choice of the treatment and prognosisevaluation. The consensus is helpful for standardizing 68Ga-Pentixafor PET/CT imaging and promoting a better diagnosis procedure in primary aldosteronism.
    • FullText(HTML)
    • References (15)
  • [1]
    Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101: 1889-1916. DOI: 10.1210/jc.2015-4061
    [2]
    Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38: 1919-1928. DOI: 10.1097/HJH.0000000000002510
    [3]
    Wang H, Wang F, Zhang Y, et al. Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings[J]. Front Endocrinol (Lausanne), 2021, 12: 663096. DOI: 10.3389/fendo.2021.663096
    [4]
    Mulatero P, Sechi LA, Williams T A, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38: 1929-1936. DOI: 10.1097/HJH.0000000000002520
    [5]
    Walenkamp A, Lapa C, Herrmann K, et al. CXCR4 Ligands: The Next Big Hit?[J]. J Nucl Med, 2017, 58: 77S-82S. DOI: 10.2967/jnumed.116.186874
    [6]
    Heinze B, Fuss CT, Mulatero P, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma[J]. Hypertension, 2018, 71: 317-325. DOI: 10.1161/HYPERTENSIONAHA.117.09975
    [7]
    Ding J, Zhang Y, Wen J, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 2656-2665. DOI: 10.1007/s00259-020-04722-0
    [8]
    Ding J, Tong A, Zhang Y, et al. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor[J]. J Nucl Med, 2022, 63: 368-375. DOI: 10.2967/jnumed.121.261964
    [9]
    Ding J, Tong A, Zhang Y, et al. Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas[J]. Clin Nucl Med, 2020, 45: 336-339. DOI: 10.1097/RLU.0000000000002946
    [10]
    Gao Y, Ding J, Cui Y, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-Pentixafor PET/CT[J]. Eur Radiol, 2022. doi: 10.1007/s00330-022-09058-x.
    [11]
    Song Y, Yang J, Shen H, et al. Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism[J]. J Hypertens, 2022, 40: 1692-1701. DOI: 10.1097/HJH.0000000000003197
    [12]
    Fu B, Zhang X, Wang GX, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma[J]. J Urol, 2011, 185: 1578-1582. DOI: 10.1016/j.juro.2010.12.051
    [13]
    中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm

    Chinese Society of Endocrinology. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020)[J]. Zhonghua Neifenmi Daixie Zazhi, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm
    [14]
    Steichen O, Zinzindohoué F, Plouin PF, et al. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review[J]. Horm Metab Res, 2012, 44: 221-227. DOI: 10.1055/s-0031-1299681
    [15]
    Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5: 689-699. DOI: 10.1016/S2213-8587(17)30135-3
    • Related Articles

  • Related Articles

    [1]ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605
    [2]TIAN Zhuang, ZHANG Shuyang. Interpretation on Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 801-806. DOI: 10.12290/xhyxzz.2024-0292
    [3]WANG Yongxuan, LI Mei, ZHANG Zhenlin, XIA Weibo. Interpretation on the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1203-1207. DOI: 10.12290/xhyxzz.2023-0364
    [4]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [5]CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. DOI: 10.12290/xhyxzz.2023-0190
    [6]LIANG Yun, WU Wenming, NIE Yongzhan, CHEN Jie. Interpretation on the Chinese Guideline for Diagnosis and Treatment of Neuroendocrine Neoplasms from The China Anti-Cancer Association(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 94-100. DOI: 10.12290/xhyxzz.2022-0607
    [7]LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271
    [8]WU Juelun, SHEN Le. Evaluation, Preparation, Decision, and Oxygenation: Interpretation on 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 421-426. DOI: 10.12290/xhyxzz.2022-0075
    [9]ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180
    [10]WANG Zi-jun, ZHOU Qi, XING Dan, YANG Nan, LUO Xu-fei, ZHANG Jing-yi, SHI Qian-ling, ZHAO Si-ya, LIU Hui, LIU Xiao, LI Qin-yuan, DU Liang, YANG Ke-hu, CHEN Yao-long. Reporting Quality of Literature Interpreting Clinical Practice Guidelines/Consensus: A Cross-sectional Study[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 260-267. DOI: 10.12290/xhyxzz.20200250

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1203) PDF downloads (481) Cited by()
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close